BLRX News

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026

Synthetic Stem Cells Market by Application, End-user, and Region - Size, Trends, Opportunities, and Forecast, 2026-2035 | AI and Cell-Free Therapies Drive 22.78% CAGR

Genesys Capital Announces Second Close of Genesys University Seed Fund, Welcoming Sunnybrook and UHN as Hospital Partners

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model